PresbiBio LLC Receives US FDA Approval to Begin Phase II Trial of
Presbia Flexivue Microlens™ Corneal Inlay

AMSTERDAM, Netherlands—November 12, 2013—PresbiBio LLC, a wholly owned subsidiary of
Presbia Holdings, a medical device company and leader in near vision restoration, announced today
that it has received conditional approval from the United States Food and Drug Administration (FDA)
of its Investigational Device Exemption (IDE) application to commence a Phase II trial of the Presbia
Microlens™, a corneal inlay.

“This is an important step in making the Presbia Microlens™, a refractive solution for the treatment of
presbyopia intended to reduce the dependency on reading glasses, available to more patients
affected by this common age-related deterioration of near vision,” said Vlad Feingold, Chief
Technology Officer and inventor of the product.

PresbiBio plans to begin its Phase II trial in the first quarter of 2014 with Dr. Mickey Gordon and Dr.
Robert Maloney as Co-Medical Monitors. The Presbia Microlens™ received the CE Mark in 2009,
making it commercially available in 40 countries across Europe and Latin America.

ABOUT PRESBIA AND THE PRESBIA FLEXIVUE MICROLENS™

Presbia Holdings is a leading ophthalmic-device company focused on the development of solutions
for presbyopia, the age-related loss of the ability to read or focus on near objects. Chief among these
approaches is the Presbia Microlens™, a 3mm-diameter lens that is implanted in the corneal stroma
of the patient’s non-dominant eye using femtosecond laser technology. The procedure requires no
general anesthesia and typical recovery periods are only a few days. The Presbia Microlens™
solution utilizes existing equipment and ophthalmic surgical techniques, and requires only minimal
additional staff training.

Further information is available at www.presbia.com.

CONTACT

Jake VANDER ZANDEN
Chief Commercial Officer
Presbia Holdings
1.720.635.2020
jake@presbia.com